Printer Friendly

NEURORECOVERY GETS ORPHAN DRUG DESIGNATION.

Neurorecovery, Inc. (NRI), a biopharmaceutical company focused on treatments for peripheral neuropathies, has announced that its request for orphan drug designation of 4-Aminopyridine has been granted for treatment of chronic functional motor and sensory deficits resulting from Guillain-Barre Syndrome (GBS).

Dr. Jay Meythaler, head of NRI's Scientific Advisory Board, commented, "We are encouraged by the orphan drug designation of 4-Aminopyridine for the treatment of chronic functional motor and sensory deficits from Guillain-Barre Syndrome. NRI's mission is to improve the functionality of patients suffering from peripheral neuropathies and this announcement supports our strategic goal to help patients suffering from peripheral neuropathies."

Edward Labry, chairman of NRI, commented, "NRI has achieved a major milestone by receiving orphan drug designation as this provides for seven years of market exclusivity in the United States for our proposed indication. Our lead product, Ampydin (IR), is an immediate release, oral administration version of 4-Aminopyridine (4-AP). We intend to develop Ampydin (IR) as a proposed treatment for a number of peripheral neuropathies."

About Neurorecovery Incorporated.

NRI is a biopharmaceutical company focused on treatment for peripheral neuropathies. Our lead product, Ampydin (IR), is an immediate release version of 4-Aminopyridine, or 4-AP. 4-Aminopyridine is currently on the FDA's compounding for compassionate use list for treatment of certain neuropathies and for spinal cord injury and MS. NRI is moving into a Phase III clinical trial with the proposed indication of 4-Aminopyridine for the treatment of chronic functional motor and sensory deficits resulting from Guillain-Barre Syndrome. The Phase IIa trial was partially funded by the National Institute of Disability, Rehab and Rehabilitation (NIDRR) and the Phase IIb trial was funded by a grant from the FDA Orphan Drug Office. The are a Delaware Corporation headquartered in Memphis, Tennessee.

For more information, visit http://www.neurorecoveryinc.com or call 901/537-2992.
COPYRIGHT 2007 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Date:Feb 1, 2007
Words:299
Previous Article:AVAA WORLD HEALTH LAUNCHES CLINICAL TRIAL FOR NEUROSKIN.
Next Article:NVENTA UPDATES DEVELOPMENT STRATEGY ON HSPE7.


Related Articles
TECHNICLONE'S ONCOLYM QUALIFIES AS ORPHAN DRUG.
Abgenix, SangStat receive orphan drug designation for acute GVHD treatment.
DOR BioPharma's GVHD treatment receives first European Orphan Medicinal Product designation.
SUPERGEN'S DECITABINE GRANTED "ORPHAN DRUG" STATUS IN EUROPE.
FDA grants ESP Pharma Orphan Drug status for IV Terlipressin for treating type 1 hepato-renal syndrome.
Udun receives FDA Orphan Drug designation for IDN-6556 in organ transplantation treatment.
SEATTLE GENETICS EXPANDS SGN-40 PROGRAM FOR LEUKEMIA.
FDA GRANTS ORPHAN DRUG DESIGNATION FOR DROXIDOPA.
Drug given a fast track; FDA gives some help to its latest `orphan'.
HANA BIOSCIENCES GETS U.S.ORPHAN DRUG DESIGNATION FOR MARQIBO.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters